Plasmid construction and small interfering RNA (siRNA)
To generate shRNAexpressing constructs, double-stranded oligos encoding the desired shRNA were cloned into single-vector inducible shRNA pSingle-tTSshRNA (Clontech). The following double-stranded oligos were inserted between XhoI/HindIII sites of pSingle-tTS- Stable U2OS shRNA clones were selected with G418 (400 µg/ml) before single cell clones were picked and analyzed. The sequences of the AAC-11 siRNAs derived from the shRNAs are the following: AAC-11 #1: 5'-(GAGAGCCAGUGAAGAUACA)dTT-3' and AAC-11 #2:
5'-( GACCUAGAACAGACCUUCA)dTT-3'. The sequence of the siRNA for Acinus was: 5'-(GAGGCCUUCUGGAUUGACA)dTT-3'.
(Invitrogen) vectors, respectively. To introduce silent mutations into the region of the Acinus cDNA targeted by the siRNA used in this study, the codons at amino acid positions 1045 and 1046 were mutated from ATT to ATA (codon 1045) and GAC to GAT (codon 1046).
Transfection, Immunoprecipitation and Immunoblot analysis and GST pull-down analysis.
293T cells (5 X 105 cells) in 60-mm dishes were transiently transfected with the expression plasmids using the JetPeiTM (Polyplus Transfection) method as per the manufacturer's instructions. 36 h after transfection, cells were lysed in 50 mM Tris/HCl pH 7.6, 150 mM NaCl containing 1% Triton-X100, 10 µg.ml-1 leupeptin and aprotinin and 0.1 mM PMSF and clarified by centrifugation at 15,000 g for 15 min. The clarified lysates were preabsorbed on protein G-Sepharose (Pharmacia) and then incubated with the indicated antibodies for 2h, followed by protein G-Sepharose agarose IgG beads. Immune complexes were washed extensively in the lysis buffer and eluted by boiling in SDS sample buffer. The eluted proteins were resolved by SDS-PAGE and detected by Western analysis with a horseradish peroxidase-conjugate T7-or Flag-antibody (Novagen). For GST Pull-down assays, GST fusion proteins were overexpressed in Escherichia coli strain BL21 and equal amounts of proteins were immobilized on glutathione-Sepharose beads. Labeled interacting proteins were prepared by in vitro transcription and translation in the presence of 35 [S]methionine using Promega's T7-coupled transcription/translation TNT kit according to the manufacturer's recommendations. After translation, equal amounts of the translation reactions were incubated with the protein-bound Sepharose beads in 100 µl of binding buffer (50 mM Tris-HCl, pH 7.6, 100 mm NaCl, 0.5% Brij, and protease inhibitors) for 3 h at 4°C. The beads were washed four times with the same buffer, boiled in SDS sample buffer. The proteins were then resolved on SDS-PAGE and visualized by autoradiography.
Apoptosis, cell cycle analysis and in-vitro caspase-3/7 assays.
Detection of phosphatidylserine on apoptotic cells was performed by using an annexin V/propidium iodide (PI) detection kit (Beckman Coulter, Immunotech, Marseille, France) according to the manufacturer. Briefly, 5 x 105 cells were incubated in the dark at 4°C with annexin V-fluorescein isothiocyanate (FITC) and 2.5 µg/mL PI in phosphate buffer for 10 minutes before 18 000 ungated events were collected within the hour by flow cytometry 
Immunocytochemistry.
Cells were fixed in 4% PFA and Acinus was detected using anti-Acinus in combination with Alexa fluor 647. Nuclei were counterstained with 4'-diamino-2-phenylindole (DAPI). Images were acquired by confocal microscopy on a Zeiss LSM 510 META confocal laser microscope (Zeiss, Oberkochen, Germany) with a Plan Apochromat 63X N.A.1.4 oil-immersion objective using the LSM510 software v4.0 (Zeiss).
Peptides uptake measurement.
Quantification of internalized FITC-labeled AAC-11 peptides was performed as described:
cells were plated in 24-well plates to about 70% confluence and incubated with various concentrations of peptides for 1 h at 37 °C. The cells were rinsed three times with Hepes buffered saline (20 mM HEPES, 150 mM NaCl, pH 7.4) supplemented with 100 μg/ml heparin. The cells were collected by trypsination and thereafter lysed (0.1 M NaOH, on ice, 1 h). Cell lysates were transferred to black 96-well plates for fluorimetric quantification of internalized peptides using a FL600 microplate fluorescence reader (Bio-Tek) with excitation/emission filter settings at 485/520 nm. The total protein concentration in each sample was determined using a protein assay kit from Bio-Rad. All experiments were repeated at least three times and always performed in triplicate. All data were corrected for background contributions by subtracting appropriate blanks and normalized against the total protein concentration in each sample. 
Figure S1
Deregulation of AAC-11 results in an increase of drug-induced effector caspases activity. U2OS control or AAC-11 shRNA-stable clones were cultured in the presence or absence of doxycycline for 48 hours. Cells were exposed to etoposide (ETO, 20 μM), camptothecin (CPT, 20 μM) for 5 hours or left untreated. Caspase-3/7 activity was measured using the Apo-ONE Homogeneous Caspase-3/7 Assay kit (Promega) according to the manufacturer's protocol. Results are presented as the mean values±standard deviation of two independent experiments carried out in triplicate. AAC-11 did not prevent apoptotic cytochrome c release nor prevent effector caspase activation following drug treatment. (A) U2OS clones stably expressing T7-tagged AAC-11 or T7-tagged AAC-11 LL/RR were exposed to etoposide or left untreated. Mitochondrial transmembrane potential loss (∆Ψm) was then determined by flow cytometry using DiOC 6 (3). Each bar represents the mean±S. D. from three independent experiments. (B) U2OS clones stably expressing T7-tagged AAC-11 or T7-tagged AAC-11 LL/RR were exposed to etoposide or left untreated. Cell extracts were separated into membrane and cytosolic fractions, and the fractionated extracts were subsequently immunobloted with the indicated antibodies. (C) U2OS clones stably expressing T7-tagged AAC-11 or T7-tagged AAC-11 LL/RR were exposed to etoposide (ETO, 20 μM), camptothecin (CPT, 20 μM) for 5 hours or left untreated. Caspase-3/7 activity was measured as in Figure S1 .
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Figure S4
Amino acid sequence of human Acinus-L was aligned to the sequence of Drosophila Acinus (CG104473). Black and gray shades indicate identical and similar residues, respectively. The minimal interacting domain for interaction with AAC-11 is squared.
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Figure S5
In-vitro interaction of AAC-11 with Acinus. 35 S-labeled Acinus-S (lane 1, 10% input) was incubated with an equal amount of glutathione Sepharose beads bound to an equal amount of GST (lane 2) or GST-AAC-11 (lane 3). Bound proteins were then eluted and analyzed by SDS-PAGE and autoradiography. 
Figure S6
Deregulation of Acinus results in an increase of drug-induced effector caspases activity. U2OS cells were transfected with siRNA to Acinus or mock siRNA. 48 hours after transfection, the cells were exposed to staurosporin (1 µM) for 3 h and caspase 3/7 activity was measured as in Figure S1 . 
Figure S7
Deregulation of AAC-11 does not inhibit apoptotic chromatin condensation. U2OS control or AAC-11 shRNA-stable clones were cultured in the presence or absence of doxycycline for 48 hours. Cells were exposed to etoposide (ETO, 10 µM, 16 h) followed by 1 µM staurosporine (STS) for another 4 h or left untreated. Apoptotic chromatin condensation was evaluated as in Figure 4B . 
Figure S8
AAC-11 expression does not prevent caspase-3-triggered proteolysis of ICAD. U2OS clones stably transfected with T7-tagged AAC-11 or T7-tagged AAC-11 LL/RR constructs were exposed to staurosporin (1 µM) for 2 h or left untreated. The cells were the lysed and the lysates analyzed by western blotting using the indicated antibodies.
